- Approval Id
- 9ced441a23783637
- Drug Approval Emc Name
- Paraserts 125mg Suppositories
- Drug Name
- Paraserts 125mg Suppositories
- Company Name
- Typharm Limited
- Company Address
- Unit 1, 39 Mahoney Green, Rackheath, Norwich, Norfolk, NR13 6JY
- Company Website
- http://typharm.com
- Company Telephone
- +44 (0)1603 722480
- Company Medical Info Direct Line
- +44 (0)2037 694160
- Company Medical Info Email
- medinfo@typharm.com
- Company Customer Care Direct Line
- +44 (0)1603 722480
- Company Stock Availability
- +44 (0)1603 722480
- Atc Code
- N02BE01
- Legal Category
- Pharmacy
- Authorisation Holder
- Amdeepcha Limited
85 Yarmouth Road
Blofield
Norwich
NR13 4LQ
UK
- Authorisation Number
- PL 19255/0010
- Authorisation Date
- 02/11/2011
- Instruction Authorisation Holder
- Amdeepcha Limited
85 Yarmouth Road
Blofield
Norwich
NR13 4LQ
UK
- Instruction Authorisation Number
- PL 19255/0010
- Instruction Authorisation Date
- 02/11/2011
- Instruction Composition
- Each suppository contains paracetamol 125 mg.
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Suppositories.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
For the treatment of mild to moderate pain and fever. Paraserts/Paracetamol Suppositories may be especially useful in patients unable to take oral forms of paracetamol, e.g. post-operatively or with nausea and vomiting.4.2 Posology and method of administration
Method of administration: rectal
\*\*Children:\*\*
1 year – 5 years: 1 -2 suppositories every 4 to 6 hours.
Dosages should be based on the child's age and weight i.e.:
1 year (10 kg) – 125 mg (1 suppository)
5 years (20 kg) – 250 mg (2 suppositories)
These doses may be repeated up to a maximum of 4 times in 24 hours. The dose should not be repeated more frequently than every 4 hours. The recommended dose should not be exceeded. Higher doses do not produce any increase in analgesic effect. The product should not be used for more than 3 days, except on the advice of a doctor\*\*.\*\* Only whole suppositories should be administered – do not break the suppository before administration4.3 Contraindications
Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, soy or peanuts.4.4 Special warnings and precautions for use
Paraserts/Paracetamol Suppositories should not be combined with other analgesic medications that contain paracetamol. Paracetamol should be given with care to patients with impaired kidney or liver function.
In general, the habitual use of painkillers, especially with combinations of more than one pain killing active ingredient, can lead to permanent kidney damage with the risk of liver failure (analgesic nephropathy).
Label and leaflet will state the following warnings:
\*\*Label\*\*:
“Immediate medical advice should be sought in the event of an overdose, even if the child seems well”.
“Do not give with any other Paracetamol-containing products.”
\*\*Leaflet\*\*:
“Immediate medical advice should be sought in the event of an overdose, even if the child seems well, because of the risk of delayed, serious liver damage.”
Cases of high anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis have been reported in patients with severe illness such as severe renal impairment and sepsis, or in patients with malnutrition or other sources of glutathione deficiency (e.g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin. If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended. The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors.4.5 Interaction with other medicinal products and other forms of interaction
The absorption of paracetamol is speeded by metaclopramide or domperidone, and absorption is reduced by colestyramine.
The anticoagulant effect of warfarin and other coumarins may be increased by long term regular daily use of paracetamol, with increased risk of bleeding. Occasional doses of paracetamol do not have a significant effect on these anticoagulants.
Enzyme-inducing medicines, such as some antiepileptic drugs (phenytoin, phenobarbital, carbamazepine) have been shown in pharmacokinetic studies to reduce the plasma AUC of paracetamol to approx. 60 %. Other substances with enzyme- inducing properties, e.g. rifampicin are also suspected of causing lowered concentrations of paracetamol. In addition, the risk of liver damage during treatment with maximum recommended doses of paracetamol will be higher in patients being treated with enzyme-inducing agents.
Caution should be taken when paracetamol is used concomitantly with flucloxacillin as concurrent intake has been associated with high anion gap metabolic acidosis due to pyroglutamic acidosis, especially in patients with risk factors (see section 4.4).4.6 Fertility, pregnancy and lactation
Epidemiological studies in human pregnancy have shown no ill effects due to paracetamol used in the recommended dosage, but patients should follow the advice of their doctor regarding its use.
Paracetamol is excreted in breast milk but not in clinically significant amounts. Available published data do not contraindicate breast feeding.4.7 Effects on ability to drive and use machines
None known.4.8 Undesirable effects
| | | |
| --- | --- | --- |
| Common >1/100 | \*Miscellaneous:\* | Redness of the rectal mucous membranes |
| Rare <1/1000 | \*General:\* \*Skin:\* \*Liver:\* \*Genitourinary:\* | Allergic reactions including skin rashes Exanthema, urticaria Liver damage Increase in creatinine (mostly secondary to hepatorenal syndrome) |
| Not Known (cannot be estimated from the available data) | \*Metabolism and nutrition disorders:\* | High anion gap metabolic acidosis |
There have been some reports of blood dyscrasias including thrombocytopenia and argranulocytosis, with the use of paracetamol-containing products, but the causal relationship has not been established.
\*\*Description of selected adverse reactions\*\*
High anion gap metabolic acidosis
Cases of high anion gap metabolic acidosis due to pyroglutamic acidosis have been observed in patients with risk factors using paracetamol (see section 4.4). Pyroglutamic acidosis may occur as a consequence of low glutathione levels in these patients.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.go.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Liver damage is possible in adults who have taken 10 g or more of paracetamol. Ingestion of 5 g or more of paracetamol may lead to liver damage if the patient has risk factors (see below).
It is considered that excess quantities of a toxic metabolite (usually adequately detoxified by glutathione when normal doses of paracetamol are ingested) become irreversibly bound to liver tissue.
\*\*Risk factors:\*\*
If the patient:
a. Is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John's Wort or other drugs that induce liver enzymes.
Or
b. Regularly consumes ethanol in excess of recommended amounts.
Or
c. Is likely to be glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.
\*\*Symptoms:\*\*
Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema, and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop in the absence of severe liver damage. Cardiac arrythmias and pancreatitis have been reported.
\*\*Management:\*\*
Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines, see BNF overdose section.
Treatment with activated charcoal should be considered if the overdose has been taken by mouth within 1 hour. Plasma paracetamol concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable alternative for remote areas, outside hospital.
Management of patients who present with serious hepatic dysfunction beyond 24h from ingestion should be discussed with NPIS or a liver unit.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic Group: Anilides, ATC Code: N02 BE01 Paracetamol is an aniline derivative with analgesic and antipyretic actions similar to those of aspirin but with no demonstrable anti-inflammatory activity. It does not affect thrombocyte aggregation or bleeding time.
Paracetamol is generally well tolerated by patients hypersensitive to acetylsalicylic acid. It produces analgesia by elevation of the pain thresholdand antipyresis through action on the hypothalamic heat-regulation centre.5.2 Pharmacokinetic properties
Paracetamol is well absorbed by both oral and rectal routes. Peak plasma concentrations occur about 2 to 3 hours after rectal administration. The plasma half life is about 2 ¼ hours and is prolonged in cirrhosis.
Paracetamol is primarily metabolised in the liver by conjugation to glucuronide and sulphate. A small amount (about 3-10% of a therapeutic dose) is metabolised by oxidation and the reactive intermediate metabolite thus formed is bound preferentially to the liver glutathione and excreted as cystein and mercapturic acid conjugates. Excretion occurs via the kidneys. 2- 3% of a therapeutic dose is excreted unchanged; 80-90% as glucuronide and sulphate and a smaller amount as cystein and mercapturic acid derivatives.5.3 Preclinical safety data
Paracetamol crosses the placenta.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction and development.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Hydrogenated fat
Soyabean lecithin6.2 Incompatibilities
None relevant.6.3 Shelf life
36 months.6.4 Special precautions for storage
Do not store above 30°C.6.5 Nature and contents of container
PVC blister packet.
In pack size of 10 suppositories.6.6 Special precautions for disposal and other handling
None.
- Instruction Content
- ## Composition
Each suppository contains paracetamol 125 mg.
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Suppositories.
## Clinical Particulars
4.1 Therapeutic indications
For the treatment of mild to moderate pain and fever. Paraserts/Paracetamol Suppositories may be especially useful in patients unable to take oral forms of paracetamol, e.g. post-operatively or with nausea and vomiting.4.2 Posology and method of administration
Method of administration: rectal
\*\*Children:\*\*
1 year – 5 years: 1 -2 suppositories every 4 to 6 hours.
Dosages should be based on the child's age and weight i.e.:
1 year (10 kg) – 125 mg (1 suppository)
5 years (20 kg) – 250 mg (2 suppositories)
These doses may be repeated up to a maximum of 4 times in 24 hours. The dose should not be repeated more frequently than every 4 hours. The recommended dose should not be exceeded. Higher doses do not produce any increase in analgesic effect. The product should not be used for more than 3 days, except on the advice of a doctor\*\*.\*\* Only whole suppositories should be administered – do not break the suppository before administration4.3 Contraindications
Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, soy or peanuts.4.4 Special warnings and precautions for use
Paraserts/Paracetamol Suppositories should not be combined with other analgesic medications that contain paracetamol. Paracetamol should be given with care to patients with impaired kidney or liver function.
In general, the habitual use of painkillers, especially with combinations of more than one pain killing active ingredient, can lead to permanent kidney damage with the risk of liver failure (analgesic nephropathy).
Label and leaflet will state the following warnings:
\*\*Label\*\*:
“Immediate medical advice should be sought in the event of an overdose, even if the child seems well”.
“Do not give with any other Paracetamol-containing products.”
\*\*Leaflet\*\*:
“Immediate medical advice should be sought in the event of an overdose, even if the child seems well, because of the risk of delayed, serious liver damage.”
Cases of high anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis have been reported in patients with severe illness such as severe renal impairment and sepsis, or in patients with malnutrition or other sources of glutathione deficiency (e.g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin. If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended. The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors.4.5 Interaction with other medicinal products and other forms of interaction
The absorption of paracetamol is speeded by metaclopramide or domperidone, and absorption is reduced by colestyramine.
The anticoagulant effect of warfarin and other coumarins may be increased by long term regular daily use of paracetamol, with increased risk of bleeding. Occasional doses of paracetamol do not have a significant effect on these anticoagulants.
Enzyme-inducing medicines, such as some antiepileptic drugs (phenytoin, phenobarbital, carbamazepine) have been shown in pharmacokinetic studies to reduce the plasma AUC of paracetamol to approx. 60 %. Other substances with enzyme- inducing properties, e.g. rifampicin are also suspected of causing lowered concentrations of paracetamol. In addition, the risk of liver damage during treatment with maximum recommended doses of paracetamol will be higher in patients being treated with enzyme-inducing agents.
Caution should be taken when paracetamol is used concomitantly with flucloxacillin as concurrent intake has been associated with high anion gap metabolic acidosis due to pyroglutamic acidosis, especially in patients with risk factors (see section 4.4).4.6 Fertility, pregnancy and lactation
Epidemiological studies in human pregnancy have shown no ill effects due to paracetamol used in the recommended dosage, but patients should follow the advice of their doctor regarding its use.
Paracetamol is excreted in breast milk but not in clinically significant amounts. Available published data do not contraindicate breast feeding.4.7 Effects on ability to drive and use machines
None known.4.8 Undesirable effects
| | | |
| --- | --- | --- |
| Common >1/100 | \*Miscellaneous:\* | Redness of the rectal mucous membranes |
| Rare <1/1000 | \*General:\* \*Skin:\* \*Liver:\* \*Genitourinary:\* | Allergic reactions including skin rashes Exanthema, urticaria Liver damage Increase in creatinine (mostly secondary to hepatorenal syndrome) |
| Not Known (cannot be estimated from the available data) | \*Metabolism and nutrition disorders:\* | High anion gap metabolic acidosis |
There have been some reports of blood dyscrasias including thrombocytopenia and argranulocytosis, with the use of paracetamol-containing products, but the causal relationship has not been established.
\*\*Description of selected adverse reactions\*\*
High anion gap metabolic acidosis
Cases of high anion gap metabolic acidosis due to pyroglutamic acidosis have been observed in patients with risk factors using paracetamol (see section 4.4). Pyroglutamic acidosis may occur as a consequence of low glutathione levels in these patients.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.go.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Liver damage is possible in adults who have taken 10 g or more of paracetamol. Ingestion of 5 g or more of paracetamol may lead to liver damage if the patient has risk factors (see below).
It is considered that excess quantities of a toxic metabolite (usually adequately detoxified by glutathione when normal doses of paracetamol are ingested) become irreversibly bound to liver tissue.
\*\*Risk factors:\*\*
If the patient:
a. Is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John's Wort or other drugs that induce liver enzymes.
Or
b. Regularly consumes ethanol in excess of recommended amounts.
Or
c. Is likely to be glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.
\*\*Symptoms:\*\*
Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema, and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop in the absence of severe liver damage. Cardiac arrythmias and pancreatitis have been reported.
\*\*Management:\*\*
Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines, see BNF overdose section.
Treatment with activated charcoal should be considered if the overdose has been taken by mouth within 1 hour. Plasma paracetamol concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable alternative for remote areas, outside hospital.
Management of patients who present with serious hepatic dysfunction beyond 24h from ingestion should be discussed with NPIS or a liver unit.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic Group: Anilides, ATC Code: N02 BE01 Paracetamol is an aniline derivative with analgesic and antipyretic actions similar to those of aspirin but with no demonstrable anti-inflammatory activity. It does not affect thrombocyte aggregation or bleeding time.
Paracetamol is generally well tolerated by patients hypersensitive to acetylsalicylic acid. It produces analgesia by elevation of the pain thresholdand antipyresis through action on the hypothalamic heat-regulation centre.5.2 Pharmacokinetic properties
Paracetamol is well absorbed by both oral and rectal routes. Peak plasma concentrations occur about 2 to 3 hours after rectal administration. The plasma half life is about 2 ¼ hours and is prolonged in cirrhosis.
Paracetamol is primarily metabolised in the liver by conjugation to glucuronide and sulphate. A small amount (about 3-10% of a therapeutic dose) is metabolised by oxidation and the reactive intermediate metabolite thus formed is bound preferentially to the liver glutathione and excreted as cystein and mercapturic acid conjugates. Excretion occurs via the kidneys. 2- 3% of a therapeutic dose is excreted unchanged; 80-90% as glucuronide and sulphate and a smaller amount as cystein and mercapturic acid derivatives.5.3 Preclinical safety data
Paracetamol crosses the placenta.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction and development.
## Pharmaceutical Particulars
6.1 List of excipients
Hydrogenated fat
Soyabean lecithin6.2 Incompatibilities
None relevant.6.3 Shelf life
36 months.6.4 Special precautions for storage
Do not store above 30°C.6.5 Nature and contents of container
PVC blister packet.
In pack size of 10 suppositories.6.6 Special precautions for disposal and other handling
None.
